Clinical trials: Are these your patients?

Journal of Allergy and Clinical Immunology

Volumn 112, Issue 5 SUPPL., 2003, Pages

  Storms, William ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE   (United States)

Author keywords

Clinical endpoints; Clinical trials; Selection bias; Surrogate markers

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; MONTELUKAST;

ASTHMA; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; FORCED EXPIRATORY VOLUME; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0242608397     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2003.09.019     Document Type: Conference Paper

References (15)

1. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 1999;52:1143-56.
2. Gross CP, Mallory R, Heiat A, Krumholz HM. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med 2002;137:10-16.
3. Jónasson G, Carlsen KH, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child 2000;83:330-3.
4. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158:1213-20.
5. Williams B, Noonan G, Reiss TF, Knorr B, Guerra J, White R, et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 2001;31:845-54.
6. Greenhalgh T. How to read a paper. Papers that report drug trials. BMJ 1997;315:480-3.
7. Zhang J, Yu C, Holgate ST, Reiss TF. Variability and lack of predictive ability of asthma end-points in clinical trials. Eur Respir J 2002;20:1102-9.
8. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289:454-65.
9. Dickersin K, Min YI. Publication bias: the problem that won't go away. Ann N Y Acad Sci 1993;703:135-46.
10. Ezzo J, Berman BM, Vickers AJ, Linde K. Complementary medicine and the Cochrane Collaboration. JAMA 1998;280:1628-30.
11. Jadad AR, Cook DJ, Jones A, Klassen TP, Tugwell P, Moher M, et al. Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. JAMA 1998;280:278-80.
12. Pich J, Carne X, Arnaiz JA, Gomez B, Trilla A, Rodes J. Role of a research ethics committee in follow-up and publication of results. Lancet 2003;361:1015-6.
13. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 1998;338:101-6.
14. Tobin MJ. Conflicts of interest and AJRCCM: restating policy and a new form to upload. Am J Respir Crit Care Med 2003;167:1161-4.
15. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999;130:487-95.